Liankang Biotechnology Group (00690) reached a strategic cooperation with the National Engineering Research Center of Wenzhou Medical University and the People's Government of Ouhai District, Wenzhou

Zhitong Finance App News, Liankang Biotechnology Group (00690) issued an announcement. Recently, in Wenzhou City, Zhejiang Province, the group officially signed a tripartite strategic cooperation agreement with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations (Wenzhou Medical University National Engineering Research Center) and the Wenzhou Ouhai District People's Government, and discussed the subsequent joint construction of the “Liankang-Wenzhou Medical University Translational Medicine Joint Innovation Laboratory” (Joint Laboratory). This collaboration will help strengthen the Group's R&D pipeline layout in the fields of dermatology, ophthalmology and metabolism-related diseases, and accelerate the strategy implementation process.

According to the agreement, the three parties will rely on their respective advantages in scientific research, industry and policy to carry out a full chain of collaborative cooperation from basic research and clinical transformation to industrialization around the application of growth factor drugs in the field of regenerative medicine. The three parties intend to thoroughly explore the synergetic mechanism of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, and develop novel compound formulations and administration systems, such as endocrine diseases represented by non-alcoholic steatohepatitis (NASH), respiratory diseases represented by asthma, and bone tissue repair. The global patient base for these diseases is huge, yet there is a significant unmet clinical need for innovative treatments. Through this cooperation and the establishment of future joint laboratories, it is expected to fill treatment gaps in multiple segmented indications and further release clinical and commercial value in the broad chronic disease market.

According to reports, the National Engineering Research Center of Wenzhou Medical University is an independent business corporation organized by Wenzhou Medical University based on the national research platform “National Engineering Research Center for Cell Growth Factor Drugs and Protein Preparations”. Under the leadership of Academician Li Xiaokun of the Chinese Academy of Engineering, it has long been deeply involved in basic research and new drug creation in the field of cell growth factor drugs, and is in a leading position in the world. Meanwhile, the People's Government of Ouhai District of Wenzhou City is an important promoter and supporter of this strategic cooperation. It is committed to building a first-class biomedical industry ecosystem. The core industry platform “China Gene Pharmaceutical Valley” has provided comprehensive spatial support and special policy support for cooperative projects from R&D, pilot testing to industrialization.

This cooperation is expected to improve the Group's R&D efficiency and success rate in the field of bioinnovative drugs, shorten the product development cycle, and enhance the overall competitiveness of the EGF/FGF segment. ^{At the same time, cooperation will also help expand the application of the Group's existing products (including Golden Peptide®, Jinyinshu®, etc.) in more clinical scenarios.}

Furthermore, the board of directors believes that this cooperation is a key step for the Group to deepen “government-school-enterprise” collaboration and integrate into a national innovation platform. It is expected to significantly accelerate the R&D and transformation process of cutting-edge innovation pipelines, further consolidate long-term competitiveness in the field of regenerative medicine, and bring long-term value to shareholders.